This is a non-core endpoint: only basic statistics are computed.
See its core counterpart CD2_INSITU_PROSTATE_EXALLC for full statistics.
Carcinoma in situ of prostate
CD2_INSITU_PROSTATE
Grade III Prostatic Intraepithelial Neoplasia: High grade prostatic intraepithelial neoplasia characterized by the presence of severe architectural and cytologic abnormalities.
Endpoint definition
↥
FinnGen phenotype data
392423 individuals
Apply sex-specific rule
Sex
only males
172961
Check conditions
not C3_PROSTATE
159321
Check pre-conditions, main-only, mode, registry filters
Hospital Discharge: ICD-10
D07.5&
Hospital discharge: ICD-9
2334
Cause of death: ICD-10
D07.5&
Cause of death: ICD-9
2334
Cancer registry: Topography ICD-O-3
C61
Cancer registry: Morphology ICD-O-3
ANY
Cancer registry: Behaviour codes
2
3 out of 7 registries used, show all original rules.
145
Check minimum number of events None
145
Include endpoints None
145
Remove individuals based on genotype QC
141
CD2_INSITU_PROSTATE
Control definitions
Controls for this endpoint are individuals that are not cases.
Extra metadata
Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF9
Parent code in ICD-10
D07
Name in latin
Carcinoma in situ oculi
Show upset plot detailing case counts by codes
Or the full data table
Similar endpoints
↥List of similar endpoints to
Carcinoma in situ of prostate
based on the number of shared cases.
Broader endpoints:
- Carcinoma in situ of prostate (controls excluding all cancers)
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
- Any ICDMAIN event in hilmo or causes of death
- Any prescribed medicine buy
Narrower endpoints:
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 141 | - | 141 |
| Unadjusted prevalence (%) | 0.04 | - | 0.08 |
| Mean age at first event (years) | 67.77 | - | 67.77 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: CD2_INSITU_PROSTATE – Carcinoma in situ of prostate
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Carcinoma in situ of prostate
↥Endpoint not on priority list, no data to show.